Peroxisome-proliferator-activated receptor γ mediates the second window of anaesthetic-induced preconditioning.
The second window of anaesthetic-induced preconditioning (APC) is afforded by the interplay of multiple signalling pathways, whereas a similar protective response is mediated by peroxisome-proliferator-activated receptor γ (PPARγ) agonists. However, a possible role of this nuclear receptor during APC has not been studied to date. We investigated the hypothesis that the second window of APC is mediated by the activation of PPARγ. New Zealand White rabbits (n = 48) were subjected to 30 min of coronary artery occlusion followed by 3 h of reperfusion. The animals received desflurane (1.0 minimal alveolar concentration), the PPARγ antagonist GW9662, as well as the combined application of both, respectively, 24 h prior to coronary artery occlusion. Infarct size was determined gravimetrically; tissue levels of 15-deoxy-(12,14)-prostaglandin J(2) (15d-PGJ(2)) and nitrite/nitrate (NO(x)), as well as PPAR DNA binding were measured using specific assays. Data are presented as means ± s.e.m. Desflurane led to a reduced myocardial infarct size (41.7 ± 2.5 versus 61.8 ± 2.8%, P < 0.05), accompanied by significantly increased PPAR DNA binding (289.9 ± 33 versus 102.9 ± 18 relative light units, P < 0.05), as well as elevated tissue levels of 15d-PGJ(2) (224.4 ± 10.2 versus 116.9 ± 14.2 pg ml(-1), P < 0.05) and NO(x) (14.9 ± 0.7 versus 5.4 ± 0.7 μm, P < 0.05). Pharmacological inhibition of PPARγ abolished these protective effects, resetting the infarct size (56.5 ± 2.9%), as well as PPAR DNA-binding activity (91.2 ± 31 relative light units) and NO(x) tissue levels (5.9 ± 0.9 μm) back to control levels. Desflurane governs a second window of APC by increasing the production of 15d-PGJ(2), subsequently activating PPARγ, resulting in a diminished myocardial infarct size by increasing the downstream availability of NO.
Department of Anesthesiology, Bayerische Julius-Maximilians-Universitt, Würzburg, Germany. lotz_c@klinik.uni-wuerzburg.de
Christopher
C
Lotz
Markus
M
Lange
Andreas
A
Redel
Jan
J
Stumpner
Johannes
J
Schmidt
Tobias
T
Tischer-Zeitz
Norbert
N
Roewer
Franz
F
Kehl
D018685:Anesthetics, Inhalation / Q000494:pharmacology*; D000813:Anilides / Q000494:pharmacology; D000818:Animals; D001158:Arteries / Q000187:drug effects / Q000503:physiopathology; D054059:Coronary Occlusion / Q000188:drug therapy; D004268:DNA-Binding Proteins / Q000378:metabolism; D000077335:Desflurane; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D019157:Ischemic Preconditioning, Myocardial / Q000379:methods; D007530:Isoflurane / Q000031:analogs & derivatives* / Q000494:pharmacology; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism*; D015425:Myocardial Reperfusion / Q000379:methods; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy* / Q000378:metabolism*; D009569:Nitric Oxide / Q000378:metabolism; D047495:PPAR gamma / Q000037:antagonists & inhibitors / Q000378:metabolism*; D015230:Prostaglandin D2 / Q000031:analogs & derivatives / Q000378:metabolism; D011817:Rabbits; D015398:Signal Transduction / Q000187:drug effects
C477819:15-deoxyprostaglandin J2; C457499:2-chloro-5-nitrobenzanilide; D018685:Anesthetics, Inhalation; D000813:Anilides; D004268:DNA-Binding Proteins; D047495:PPAR gamma; D009569:Nitric Oxide; D000077335:Desflurane; D007530:Isoflurane; D015230:Prostaglandin D2